The History of CGC
The History of CGC
The Cancer Genomics Consortium (CGC) is a non-profit organization formed in August 2009 by a group of clinical cytogeneticists, molecular geneticists, and molecular pathologists, who were interested in applying microarray, sequencing, and other molecular profiling technologies to cancer diagnosis and cancer research.![](https://host8.viethwebhosting.com/~cgc/photos/55276_10152019130254.jpg)
![](https://host8.viethwebhosting.com/~cgc/photos/53931_08132019125450.jpg)
![](https://cancergenomics.org/photos/56234_11202019185718.jpg)
![](https://host8.viethwebhosting.com/~cgc/photos/54338_08282019144701.jpg)
- The first CGC-sponsored multi-center cross-platform cytogenomic microarray study, published in Cancer Genetics in 2015
- Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders, a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC).
- Evidence based reviews describing current concepts and best practices for assessing genomic aberrations in plasma cell disorders, chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms, CNS neoplasias, renal cell neoplasias, breast cancer, and B-lymphoblastic leukemia/lymphoma.